



Angela Blake

Partner

T: 416.777.4889 / T: 604.891.5350 / E: blakea@bennettjones.com

Toronto / Vancouver

EDUCATION

University of Victoria, BA (Political Science), 2003

University of British Columbia, LLB, 2007

BAR ADMISSIONS

British Columbia, 2008

Ontario, 2019

Based in Toronto and Vancouver, Angela Blake advises Canadian and international public and private companies and private equity groups on mergers and acquisitions, securities and corporate finance matters. She is able to quickly understand her clients' strategic business objectives and provide creative solutions regarding complex agreements and transaction structures, raising capital and M&A.

Angela's transactional experience includes public and private M&A (both buy and sell side), public listings, private placement financings, prospectus offerings and reverse takeovers. She also advises on a wide range of corporate governance topics, including ESG matters, governance policies for boards of directors, regulatory compliance and continuous disclosure requirements, and has assisted special committees advising on responses to hostile takeovers and other special transactions.

Angela represents clients across a broad spectrum of industries, including mining, healthcare, technology, entertainment, cannabis, psychedelics and Web3 digital assets. She is passionate about providing her clients with pragmatic advice and an exceptional level of service, so that they can be comfortable knowing that they will have her support at critical times.

Angela is currently Chair of the Ontario Local Advisory Committee of the TSX Venture Exchange and a member of its National Advisory Committee. She previously sat on its

British Columbia Local Advisory Committee and as a member of the Events Committee of the Women's Leadership Circle Advisory Board at the Greater Vancouver Board of Trade.

Angela is also a strong supporter of the BC Cancer Foundation and previously sat on the Organizing Committee of its annual Hope Couture fundraising event, which raised almost \$2 million for cancer research and care during her three-year tenure.